Status:
TERMINATED
RAndomized Controlled Trial of a Multiple INtervention proGram to Decrease Heart Failure Rehospitalization
Lead Sponsor:
French Cardiology Society
Collaborating Sponsors:
Bayer
Conditions:
Heart Decompensation
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
The prevalence of heart failure (HF) is constantly increasing in France due to the aging of the population, better management of etiological factors and improved treatments (drug / interventional). On...
Detailed Description
The aim of this study is to demonstrate the value of a multiple intervention program in reducing early readmissions for heat failure in patients hospitalized for cardiac decompensation. This work wil...
Eligibility Criteria
Inclusion
- Heart decompensation requiring hospitalization and the use of intravenous diuretic therapy
- Left Ventricular Ejection Fraction ≤ 40%.
Exclusion
- Hospitalization for cardiac decompensation leading to an invasive procedure (valve, coronary, etc.).
- Acute reversible cause of heart failure.
- Incurable disease (other than heart failure) or estimated life expectancy of less than one year.
- Patient transferred directly to another department or cardiac rehabilitation center.
- Significant cognitive impairment.
- Patient without cell phone or email.
- Linguistic or psychic refusal or inability to sign the informed consent.
- Current participation in a clinical tria
Key Trial Info
Start Date :
July 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 20 2024
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04703504
Start Date
July 15 2022
End Date
September 20 2024
Last Update
October 4 2024
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Paul d'Egine
Champigny-sur-Marne, France
2
Hôpital Henri Mondor
Créteil, France
3
Hôpital Simone Veil
Eaubonne, France
4
Hôpitaux Nord-Ouest de Villefranche
Gleizé, France, 69655